Welcome to Genopore
Genopore is developing the future of protein identification
Single Molecule Protein Identification
At Genopore, we are pioneering the world's first digital protein identification and quantification system. Our technology leverages direct optical detection at the single-molecule level to provide unparalleled insights into the proteome.
Why Proteomics Matters?
Proteins are the main functional entities of the cell and therefore they provide the most relevant information regarding cellular functions. Measuring proteins directly provides the most accurate and actionable insight into cellular function, disease mechanisms, and treatment response.
Unlike genes or transcripts, which represent “potential”, proteins reveal what’s actually happening in real time This makes proteomics critical for:
-
Disease Mechanism and Early Disease Detection: Protein expression profiles can explain disease mechanisms and signal disease before symptoms appear.
-
Precision Medicine: Most drugs today target proteins, making accurate protein profiling is essential for targeted therapy.
-
Biomarker Discovery: Identify functional markers for diagnosis, prognosis, and monitoring.
By directly analyzing the proteome, researchers can gain a real-time, functional understanding of cellular states, identify actual disease drivers, discover effective biomarkers, and pinpoint direct therapeutic targets that are actively at play in health and disease.
Genomics
40,000 genes
Transcriptomics
150,000 transcripts
Proteomics
1,000,000 proteins
About
At Genopore, we are building the world’s first digital protein identification and quantitation system based on direct optical detection at the single-molecule level.
Driven by the need for deeper, faster, and more accessible protein insights, our technology enables whole-protein identification without the complexity of mass spectrometry or the limitations of affinity-based methods. By combining chemo-selective protein labeling, solid-state nanopore translocation, and AI-powered optical readout, Genopore delivers unmatched sensitivity, dynamic range, and scalability.
From early disease detection to next-generation drug discovery, our mission is to unlock the full potential of proteomics—one molecule at a time.
Our Technology
Genopore proprietary and innovative technology was developed by co-founder Professor Amit Meller,
a pioneer in the nanopore biosensing field. This technology was recently highlighted by the prestigious Nature journal as one of the key technologies to watch.
Key advantages of our technology
Workflow
- Simple sample preparation
- Low-cost reagents and consumables
Performance
- Wide coverage
- Detection of low abundance proteins
- High sensitivity and dynamic range
Full length
- Full length proteins are read (no break down to peptides)
- Better identification accuracy
Throughput
- High and scalable throughput
- Ability to read multiple samples per day with minimal volume needs
- Provides results in less than one hour
- Direct protein optical readout
Time to results
Our Team
Ariel Notcovich,
Interim CEO and CPO
Ariel is a seasoned executive leader with over 20 years of experience in the biotech and life sciences industry, specializing in bringing platforms, instrumentation, and products to market. Starting his career as a founder, he established ProteOptics Ltd. based on his Ph.D. research, successfully leading the company to acquisition by Bio-Rad Laboratories in 2006. At Bio-Rad, he drove R&D and product development, leading a 180-person organization. He later served as CEO of Biodesy Inc., where he successfully launched a new product before leading a strategic pivot to a drug discovery platform company, BlueLight Therapeutics Inc.
Yigal Leiba, VP R&D
Yigal is a seasoned technology leader with a strong history of innovation in advanced systems. Before co-founding Genopore, he served as CTO of Siklu Communications, a company he co-founded in 2007. His career includes co-founding Amber Wireless and leading the creation of the world’s first OFDMA chip at Runcom, a technology later adopted into 4G and 5G cellular standards. Earlier, he was a chief engineer at Alvarion and an engineer in a leading Israeli intelligence technology unit. He holds a B.Sc. in Electrical Engineering from the Technion.
Oren Mansour, COO
Oren is a serial entrepreneur with 30 years of experience in the semiconductors and communication industry, he brings a proven track record of leading operations, finance, and business development. Prior to co-founding Genopore Oren served as the COO of Sckipio Technologies, a company he co-founded in 2012, where he drove the company's financial and operational strategy. Prior to this, he held senior leadership roles at CopperGate/Sigma Designs and R&D positions at Motorola Communications. Oren holds an MBA and a B.Sc. in Electrical Engineering from Tel Aviv University.
Aviv Sagi, CFO
A Certified Public Accountant and MBA. Aviv brings over 15 years of experience from CFO and Controller roles in both startups and multinational corporations. Proven track record of financial leadership, having guided a wide range of companies through various stages of growth.
Our Board
Dr. Noga Yerushalmi,
Interim Chair and Director
Noga Yerushalmi, PhD, is an Investment Director on the Biotechnology team at M-entures. With over two decades of experience in the Israeli biotech industry, she has held key leadership roles at companies like Zetiq and Rosetta Genomics, and was a co-founder of the FutuRx incubator. Her expertise spans drug discovery, business development, and company creation. Noga holds a PhD from Tel-Aviv University and completed a postdoctoral fellowship at the NIH.
Dr. Frank Bulens, Director
Frank Bulens, Phd, is a Partner at IMEC.Xpand. Frank has more than 25 years of venture capital experience in the health-tech sector. Frank is an industrial engineer in chemistry/biochemistry and obtained a Master Degree as well as a PhD in Medical Sciences at the University of Leuven, Belgium.
Prof. Amit Meller,
Founder and Director
Amit Meller, Ph.D., is a highly accomplished professor and researcher in biophysics and biomedical engineering with extensive experience at top-tier institutions. He holds a Ph.D. in Physics from the Weizmann Institute of Science, followed by postdoctoral work at Harvard University, where he pioneered the development of nanopore sensors for DNA sequencing. His research, cited over 15,000 times, focuses on developing and applying single-molecule methods to study biological systems, including protein translation, biosensors for molecular diagnostics, and ultra-sensitive sensing in live cells.
Dr. Anat Cohen-Dayag,
Independent Director
Dr. Anat Cohen-Dayag is a highly experienced biotech leader with over 25 years in both R&D and executive roles. Anat serves as the president of Compugen, a therapeutic discovery and development firm focused on immuno-oncology.
Prof. Boaz Golany, Observer
Boaz Golany is an Emeritus Professor and former Dean of the Industrial Engineering & Management Faculty at the Technion. He has a history of leadership at the university, having also served as both the Vice President for External Relations and Resource Development and the Executive Vice President and Director General. He earned his B.Sc. (cum laude) from the Technion in 1982 and a doctorate from the University of Texas at Austin in 1985.
Careers
As an early-stage startup, Genepore is in continuous grow and we are always interested to bring great talent to our team in the areas of Biochemistry, Engineering, Systems Integration, Scientists and RAs.
We are always on the lookout for talented and dedicated individuals. Please feel free to contact us directly, even if you do not see your position listed here.
Investors
Genopore is funded and supported by leading strategic investors and venture capital firms.
